OhhMed launches UK trial of Vertica after prostate cancer surgery

By AI, Created 3:20 PM UTC, May 20, 2026, /AGP/ – OhhMed Medical has started a UK clinical trial of its Vertica device in men recovering from radical prostatectomy, with London’s King Edward VII Hospital and St. Peter’s Andrology leading the study. The 12-month trial will test whether adding radiofrequency therapy to standard rehabilitation improves erectile recovery and related outcomes.

Why it matters: - Post-prostatectomy erectile dysfunction is one of the most common long-term complications after radical prostatectomy. - The UK study will test whether earlier use of Vertica during recovery can improve long-term functional outcomes for men after prostate cancer surgery. - The trial adds to growing clinical data on radiofrequency technology in male urology.

What happened: - OhhMed Medical Ltd. announced the launch of a UK clinical trial evaluating its Vertica device in men recovering from radical prostatectomy. - The trial is being run with St. Peter’s Andrology at King Edward VII Hospital in London. - Associate Professor Wai Gin Lee is the Principal Investigator. - The study will evaluate Vertica radiofrequency therapy alongside standard pharmaceutical treatment for erectile rehabilitation. - OhhMed is also running a U.S. clinical trial of Vertica for erectile dysfunction with Cleveland Clinic and Baylor College of Medicine in Houston.

The details: - Vertica delivers non-invasive radiofrequency energy intended to support tissue remodelling and vascular function. - The investigation is prospective. - Participants will be followed for 12 months. - The rehabilitation protocol combines scheduled Vertica use with standard PDE5 inhibitor therapy. - Primary and secondary endpoints include erectile function recovery, patient-reported quality of life and changes in penile tissue measurements over time. - OhhMed said the Vertica platform is being evaluated through ongoing clinical research programmes in male sexual health and rehabilitation. - The company is advancing clinical programmes in erectile dysfunction, post-prostatectomy rehabilitation and restorative urology through collaborations in the UK, Europe and the United States. - OhhMed’s broader strategy includes technologies for home use and clinical settings.

Between the lines: - The trial reflects a push to move beyond symptom management and test restorative approaches in post-surgical rehabilitation. - By pairing device therapy with standard medication, the study is designed to see whether a combined protocol can improve outcomes more than medication alone. - The company is trying to build a broader evidence base for radiofrequency treatment in male urology.

What’s next: - The study will track outcomes over the next 12 months. - Results should show whether early intervention with Vertica can improve erectile recovery and tissue measures after prostate surgery. - OhhMed expects the trial to add to the clinical evidence supporting radiofrequency technology in male urology.

The bottom line: - OhhMed is betting that Vertica can play a role in post-prostatectomy recovery, and the UK trial will help determine whether the device has a meaningful clinical benefit.